

# Primary Immunodeficiency Therapeutic Market, Global Outlook and Forecast 2022-2028

https://marketpublishers.com/r/P565E13D53A2EN.html

Date: June 2022

Pages: 63

Price: US\$ 3,250.00 (Single User License)

ID: P565E13D53A2EN

# **Abstracts**

Primary immunodeficiencies are a group of different disorders in which part of the body's immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases.

This report contains market size and forecasts of Primary Immunodeficiency Therapeutic in Global, including the following market information:

Global Primary Immunodeficiency Therapeutic Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Primary Immunodeficiency Therapeutic market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast



period 2022-2028.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Immunoglobulin Replacement Therapy Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Primary Immunodeficiency Therapeutic include Baxter International, Takeda Pharmaceutical, CSL Limited, Octapharma, Kedrion Biopharma, Bio Products Laboratory, LFB group, Grifols and Lupin Pharmaceuticals. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Primary Immunodeficiency Therapeutic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Primary Immunodeficiency Therapeutic Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Primary Immunodeficiency Therapeutic Market Segment Percentages, by Type, 2021 (%)

Immunoglobulin Replacement Therapy

Stem Cell or Bone Marrow Transplantation

Antibiotic Therapy

Gene Therapy

Others

Global Primary Immunodeficiency Therapeutic Market, by Application, 2017-2022, 2023-2028 (\$ millions)



Global Primary Immunodeficiency Therapeutic Market Segment Percentages, by Application, 2021 (%)

Antibo	dy Deficiency
Cellula	ar Immunodeficiency
Innate	Immune Disorders
Others	3
	y Immunodeficiency Therapeutic Market, By Region and Country, 023-2028 (\$ Millions)
	y Immunodeficiency Therapeutic Market Segment Percentages, Byountry, 2021 (%)
North	America
	US
	Canada
	Mexico
Europ	е
	Germany
	France
	U.K.
	Italy
	Russia



	Nordic Countries
	D 1
	Benelux
	Rest of Europe
Asia	
	China
	Japan
	South Korea
	Southeast Asia
	India
	Rest of Asia
South	America
	Brazil
	Argentina
	Rest of South America
Middle	East & Africa
	Turkey
	Israel
	Saudi Arabia
	UAE
	Rest of Middle East & Africa



# **Competitor Analysis**

The report also provides analysis of leading market participants including:

Key companies Primary Immunodeficiency Therapeutic revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Primary Immunodeficiency Therapeutic revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Baxter International

Takeda Pharmaceutical

CSL Limited

Octapharma

Kedrion Biopharma

Bio Products Laboratory

LFB group

Grifols

Lupin Pharmaceuticals



# **Contents**

#### 1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Primary Immunodeficiency Therapeutic Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Primary Immunodeficiency Therapeutic Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
- 1.5.3 Base Year
- 1.5.4 Report Assumptions & Caveats

# 2 GLOBAL PRIMARY IMMUNODEFICIENCY THERAPEUTIC OVERALL MARKET SIZE

- 2.1 Global Primary Immunodeficiency Therapeutic Market Size: 2021 VS 2028
- 2.2 Global Primary Immunodeficiency Therapeutic Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

#### **3 COMPANY LANDSCAPE**

- 3.1 Top Primary Immunodeficiency Therapeutic Players in Global Market
- 3.2 Top Global Primary Immunodeficiency Therapeutic Companies Ranked by Revenue
- 3.3 Global Primary Immunodeficiency Therapeutic Revenue by Companies
- 3.4 Top 3 and Top 5 Primary Immunodeficiency Therapeutic Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Primary Immunodeficiency Therapeutic Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Players in Global Market
  - 3.6.1 List of Global Tier 1 Primary Immunodeficiency Therapeutic Companies
- 3.6.2 List of Global Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic



#### Companies

#### 4 MARKET SIGHTS BY PRODUCT

- 4.1 Overview
- 4.1.1 by Type Global Primary Immunodeficiency Therapeutic Market Size Markets, 2021 & 2028
  - 4.1.2 Immunoglobulin Replacement Therapy
  - 4.1.3 Stem Cell or Bone Marrow Transplantation
  - 4.1.4 Antibiotic Therapy
  - 4.1.5 Gene Therapy
  - 4.1.6 Others
- 4.2 By Type Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
- 4.2.1 By Type Global Primary Immunodeficiency Therapeutic Revenue, 2017-2022
- 4.2.2 By Type Global Primary Immunodeficiency Therapeutic Revenue, 2023-2028
- 4.2.3 By Type Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028

#### 5 SIGHTS BY APPLICATION

- 5.1 Overview
- 5.1.1 By Application Global Primary Immunodeficiency Therapeutic Market Size, 2021 & 2028
  - 5.1.2 Antibody Deficiency
  - 5.1.3 Cellular Immunodeficiency
  - 5.1.4 Innate Immune Disorders
  - **5.1.5 Others**
- 5.2 By Application Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
- 5.2.1 By Application Global Primary Immunodeficiency Therapeutic Revenue, 2017-2022
- 5.2.2 By Application Global Primary Immunodeficiency Therapeutic Revenue, 2023-2028
- 5.2.3 By Application Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028

#### **6 SIGHTS BY REGION**

6.1 By Region - Global Primary Immunodeficiency Therapeutic Market Size, 2021 &



#### 2028

- 6.2 By Region Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
  - 6.2.1 By Region Global Primary Immunodeficiency Therapeutic Revenue, 2017-2022
  - 6.2.2 By Region Global Primary Immunodeficiency Therapeutic Revenue, 2023-2028
- 6.2.3 By Region Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
- 6.3 North America
- 6.3.1 By Country North America Primary Immunodeficiency Therapeutic Revenue, 2017-2028
  - 6.3.2 US Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  - 6.3.3 Canada Primary Immunodeficiency Therapeutic Market Size, 2017-2028
- 6.3.4 Mexico Primary Immunodeficiency Therapeutic Market Size, 2017-2028 6.4 Europe
- 6.4.1 By Country Europe Primary Immunodeficiency Therapeutic Revenue, 2017-2028
  - 6.4.2 Germany Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  - 6.4.3 France Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  - 6.4.4 U.K. Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  - 6.4.5 Italy Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  - 6.4.6 Russia Primary Immunodeficiency Therapeutic Market Size, 2017-2028
- 6.4.7 Nordic Countries Primary Immunodeficiency Therapeutic Market Size, 2017-2028
- 6.4.8 Benelux Primary Immunodeficiency Therapeutic Market Size, 2017-20286.5 Asia
  - 6.5.1 By Region Asia Primary Immunodeficiency Therapeutic Revenue, 2017-2028
  - 6.5.2 China Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  - 6.5.3 Japan Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  - 6.5.4 South Korea Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  - 6.5.5 Southeast Asia Primary Immunodeficiency Therapeutic Market Size, 2017-2028
- 6.5.6 India Primary Immunodeficiency Therapeutic Market Size, 2017-2028
- 6.6 South America
- 6.6.1 By Country South America Primary Immunodeficiency Therapeutic Revenue, 2017-2028
  - 6.6.2 Brazil Primary Immunodeficiency Therapeutic Market Size, 2017-2028
- 6.6.3 Argentina Primary Immunodeficiency Therapeutic Market Size, 2017-2028 6.7 Middle East & Africa
- 6.7.1 By Country Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, 2017-2028
- 6.7.2 Turkey Primary Immunodeficiency Therapeutic Market Size, 2017-2028



- 6.7.3 Israel Primary Immunodeficiency Therapeutic Market Size, 2017-2028
- 6.7.4 Saudi Arabia Primary Immunodeficiency Therapeutic Market Size, 2017-2028
- 6.7.5 UAE Primary Immunodeficiency Therapeutic Market Size, 2017-2028

#### **7 PLAYERS PROFILES**

- 7.1 Baxter International
  - 7.1.1 Baxter International Corporate Summary
  - 7.1.2 Baxter International Business Overview
- 7.1.3 Baxter International Primary Immunodeficiency Therapeutic Major Product Offerings
- 7.1.4 Baxter International Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  - 7.1.5 Baxter International Key News
- 7.2 Takeda Pharmaceutical
  - 7.2.1 Takeda Pharmaceutical Corporate Summary
  - 7.2.2 Takeda Pharmaceutical Business Overview
- 7.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Major Product Offerings
- 7.2.4 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  - 7.2.5 Takeda Pharmaceutical Key News
- 7.3 CSL Limited
  - 7.3.1 CSL Limited Corporate Summary
  - 7.3.2 CSL Limited Business Overview
  - 7.3.3 CSL Limited Primary Immunodeficiency Therapeutic Major Product Offerings
- 7.3.4 CSL Limited Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
- 7.3.5 CSL Limited Key News
- 7.4 Octapharma
  - 7.4.1 Octapharma Corporate Summary
  - 7.4.2 Octapharma Business Overview
  - 7.4.3 Octapharma Primary Immunodeficiency Therapeutic Major Product Offerings
- 7.4.4 Octapharma Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  - 7.4.5 Octapharma Key News
- 7.5 Kedrion Biopharma
  - 7.5.1 Kedrion Biopharma Corporate Summary
  - 7.5.2 Kedrion Biopharma Business Overview



- 7.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Major Product Offerings
- 7.5.4 Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  - 7.5.5 Kedrion Biopharma Key News
- 7.6 Bio Products Laboratory
  - 7.6.1 Bio Products Laboratory Corporate Summary
  - 7.6.2 Bio Products Laboratory Business Overview
- 7.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Major Product Offerings
- 7.6.4 Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  - 7.6.5 Bio Products Laboratory Key News
- 7.7 LFB group
  - 7.7.1 LFB group Corporate Summary
  - 7.7.2 LFB group Business Overview
  - 7.7.3 LFB group Primary Immunodeficiency Therapeutic Major Product Offerings
- 7.7.4 LFB group Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  - 7.7.5 LFB group Key News
- 7.8 Grifols
  - 7.8.1 Grifols Corporate Summary
  - 7.8.2 Grifols Business Overview
  - 7.8.3 Grifols Primary Immunodeficiency Therapeutic Major Product Offerings
- 7.8.4 Grifols Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
- 7.8.5 Grifols Key News
- 7.9 Lupin Pharmaceuticals
  - 7.9.1 Lupin Pharmaceuticals Corporate Summary
  - 7.9.2 Lupin Pharmaceuticals Business Overview
- 7.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Major Product Offerings
- 7.9.4 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  - 7.9.5 Lupin Pharmaceuticals Key News

#### **8 CONCLUSION**

#### 9 APPENDIX



- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer



# **List Of Tables**

#### LIST OF TABLES

- Table 1. Primary Immunodeficiency Therapeutic Market Opportunities & Trends in Global Market
- Table 2. Primary Immunodeficiency Therapeutic Market Drivers in Global Market
- Table 3. Primary Immunodeficiency Therapeutic Market Restraints in Global Market
- Table 4. Key Players of Primary Immunodeficiency Therapeutic in Global Market
- Table 5. Top Primary Immunodeficiency Therapeutic Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global Primary Immunodeficiency Therapeutic Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global Primary Immunodeficiency Therapeutic Revenue Share by Companies, 2017-2022
- Table 8. Global Companies Primary Immunodeficiency Therapeutic Product Type
- Table 9. List of Global Tier 1 Primary Immunodeficiency Therapeutic Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type Global Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type Primary Immunodeficiency Therapeutic Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type Primary Immunodeficiency Therapeutic Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application Global Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application Primary Immunodeficiency Therapeutic Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application Primary Immunodeficiency Therapeutic Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region Global Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region Global Primary Immunodeficiency Therapeutic Revenue (US\$, Mn), 2017-2022
- Table 19. By Region Global Primary Immunodeficiency Therapeutic Revenue (US\$, Mn), 2023-2028
- Table 20. By Country North America Primary Immunodeficiency Therapeutic Revenue,



(US\$, Mn), 2017-2022

Table 21. By Country - North America Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2023-2028

Table 30. Baxter International Corporate Summary

Table 31. Baxter International Primary Immunodeficiency Therapeutic Product Offerings

Table 32. Baxter International Primary Immunodeficiency Therapeutic Revenue (US\$, Mn), (2017-2022)

Table 33. Takeda Pharmaceutical Corporate Summary

Table 34. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Product Offerings

Table 35. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue (US\$, Mn), (2017-2022)

Table 36. CSL Limited Corporate Summary

Table 37. CSL Limited Primary Immunodeficiency Therapeutic Product Offerings

Table 38. CSL Limited Primary Immunodeficiency Therapeutic Revenue (US\$, Mn), (2017-2022)

Table 39. Octapharma Corporate Summary

Table 40. Octapharma Primary Immunodeficiency Therapeutic Product Offerings

Table 41. Octapharma Primary Immunodeficiency Therapeutic Revenue (US\$, Mn), (2017-2022)

Table 42. Kedrion Biopharma Corporate Summary

Table 43. Kedrion Biopharma Primary Immunodeficiency Therapeutic Product Offerings

Table 44. Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue (US\$,



Mn), (2017-2022)

Table 45. Bio Products Laboratory Corporate Summary

Table 46. Bio Products Laboratory Primary Immunodeficiency Therapeutic Product Offerings

Table 47. Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue (US\$, Mn), (2017-2022)

Table 48. LFB group Corporate Summary

Table 49. LFB group Primary Immunodeficiency Therapeutic Product Offerings

Table 50. LFB group Primary Immunodeficiency Therapeutic Revenue (US\$, Mn), (2017-2022)

Table 51. Grifols Corporate Summary

Table 52. Grifols Primary Immunodeficiency Therapeutic Product Offerings

Table 53. Grifols Primary Immunodeficiency Therapeutic Revenue (US\$, Mn), (2017-2022)

Table 54. Lupin Pharmaceuticals Corporate Summary

Table 55. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Product Offerings

Table 56. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue (US\$, Mn), (2017-2022)



# **List Of Figures**

#### LIST OF FIGURES

- Figure 1. Primary Immunodeficiency Therapeutic Segment by Type in 2021
- Figure 2. Primary Immunodeficiency Therapeutic Segment by Application in 2021
- Figure 3. Global Primary Immunodeficiency Therapeutic Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Primary Immunodeficiency Therapeutic Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Primary Immunodeficiency Therapeutic Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Primary Immunodeficiency Therapeutic Revenue in 2021
- Figure 8. By Type Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
- Figure 9. By Application Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
- Figure 10. By Region Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
- Figure 11. By Country North America Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
- Figure 12. US Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country Europe Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
- Figure 16. Germany Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028 Figure 20. Russia Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Primary Immunodeficiency Therapeutic Revenue, (US\$,



Mn), 2017-2028

Figure 22. Benelux Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028

Figure 24. China Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 28. India Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028

Figure 30. Brazil Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028

Figure 33. Turkey Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Primary Immunodeficiency Therapeutic Revenue, (US\$, Mn), 2017-2028

Figure 37. Baxter International Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. CSL Limited Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Octapharma Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)



Figure 41. Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. LFB group Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Grifols Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)



#### I would like to order

Product name: Primary Immunodeficiency Therapeutic Market, Global Outlook and Forecast 2022-2028

Product link: https://marketpublishers.com/r/P565E13D53A2EN.html

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/P565E13D53A2EN.html">https://marketpublishers.com/r/P565E13D53A2EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970